With these insights, PlexusDx can fine-tune your dosing strategy, medication choice (injectable semaglutide, oral semaglutide, or tirzepatide alternatives), and complementary protocols to minimize stomach pain while maximizing your weight loss outcomes
The FDA-reviewed prescribing information for Wegovy (semaglutide 2.4 mg) discloses that in the SELECT cardiovascular outcomes trial - which enrolled adults with established cardiovascular disease - hip and pelvis fractures were reported more often in female patients on Wegovy than in those on placebo: 1% (24 of 2,448 patients) versus 0.2% (5 of 2,424 patients)
Volume Considerations NAD+ injections in this protocol range from 0.15 mL (50 mg dose) to 0.30 mL (100 mg dose)
Their use, guided by careful consideration, ongoing research, and a patient-centered approach, exemplifies the advances and challenges in modern pharmacotherapy